Middle East & Africa Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), and End User

Description

List of Tables

The Middle East & Africa human vaccine adjuvants market was valued at US$ 49.18 million in 2022 and is expected to reach US$ 119.37 million by 2030; it is estimated to register a CAGR of 11.7% from 2022 to 2030.

Rising prevalence of chronic diseases Bolsters Middle East & Africa Human Vaccine Adjuvants Market

The rising prevalence of chronic diseases is fueling the demand for vaccine adjuvants. Adjuvants are added to vaccines to enhance the efficacy and body's immune response. They help improve the effectiveness of vaccines by stimulating a stronger and longer-lasting immune response. As the demand for vaccines to prevent and manage chronic diseases continues to grow, the demand for adjuvants also increases. Chronic diseases such as cardiovascular diseases, cancer, diabetes, and respiratory diseases are rising globally. According to the World Health Organization, the most noncommunicable disease-related deaths are cardiovascular diseases, accounting for ~17 million people each year, followed by cancers, chronic respiratory diseases, and diabetes (including deaths associated with the kidney). Furthermore, according to the World Heart Federation, high cholesterol causes 4.4 million deaths yearly, and ?24% of cardiovascular-related deaths are attributable to high low-density lipoprotein (LDL) cholesterol. Thus, the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. The prevalence of hepatitis is also increasing. Adjuvants in hepatitis vaccines aim to elicit robust and durable immunity, particularly in populations with suboptimal responses to standard vaccine formulations, such as those with underlying medical conditions or age-related immune senescence. According to the WHO, more than 350 million people worldwide live with hepatitis B or C. Among all types of hepatitis, several are preventable through vaccination. As per a study by WHO, an estimated 4.5 million premature deaths due to hepatitis could be prevented in low- and middle-income countries by 2030 through vaccination. Thus, the increasing prevalence of chronic diseases drives the growth of the Middle East & Africa human vaccine adjuvants market.

Middle East & Africa Human Vaccine Adjuvants Market Overview

Saudi Arabia has planned to localize 40% of the pharmaceutical sector and reduce its import dependence as part of its National Transformation Program. In Saudi Arabia, economic and social changes have led to a shift in sedentary lifestyles, leading to an increasing prevalence of obesity and a projected rise in metabolic syndrome. Furthermore, a lack of disease awareness and knowledge about disease transmission among patients has increased the prevalence of infectious diseases in the country. For instance, according to a study, "Hepatitis B virus infection in Saudi Arabia and the UAE: Public health challenges and their remedial measures," published in PubMed in 2023, Saudi Arabia faces critical challenges in Hepatitis B virus treatment and management even after implementing a mass vaccination program. Similarly, according to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, Saudi Arabia has a population of 10.7 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Thus, the increasing prevalence of infectious diseases in the UAE fuels the demand for human vaccine adjuvants. In recent years, the Kingdom of Saudi Arabia has invested substantially in the healthcare and pharmaceutical sectors, aiming to enhance domestic production, research, and development capabilities. This strategic focus has set the stage for potential growth, influencing the Middle East & Africa human vaccine adjuvants market. In Saudi Arabia, the King Fahd Medical City, King Faisal Specialist Hospital & Research Centre, and the Ministry of Health are among the institutions actively involved in advancing healthcare research, including those related to vaccines and adjuvants. Such investment in research facilities and medical infrastructure signals a commitment to contributing to the global vaccine landscape. It is also projected to pave the way for adjuvant research and development advancements.

Middle East & Africa Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Human Vaccine Adjuvants Market Segmentation

The Middle East & Africa human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the Middle East & Africa human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the Middle East & Africa human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the Middle East & Africa human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the Middle East & Africa human vaccine adjuvants market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa human vaccine adjuvants market share in 2022.

Novartis AG, CSL Ltd, Seppic SA, Croda International Plc, Novavax Inc, and Phibro Animal Health Corp are some of the leading companies operating in the Middle East & Africa human vaccine adjuvants market.

Product Code: BMIRE00030455

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Middle East & Africa Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 Middle East & Africa Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Chronic Diseases
- 4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
- 4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
- 4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
- 4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - Middle East & Africa Market Analysis

5.1 Middle East & Africa Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Middle East & Africa Human Vaccine Adjuvants Market Forecast Analysis

6. Middle East & Africa Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant
- 6.1.1 Overview
- 6.1.2 Particulate Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
- 6.2.1 Overview
- 6.2.2 Emulsion Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
- 6.3.1 Overview
- 6.3.2 Combination Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Middle East & Africa Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza
- 7.1.1 Overview
- 7.1.2 Influenza: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
- 7.2.1 Overview
- 7.2.2 Hepatitis: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
- 7.3.1 Overview
- 7.3.2 Human Papilloma Virus (HPV): Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Overview
- 8.1.2 Pharmaceutical and Biotechnology Companies: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
- 8.2.1 Overview
- 8.2.2 CMOs and CROs: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Human Vaccine Adjuvants Market - Country Analysis

9.1 Middle East & Africa
- 9.1.1 Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 9.1.1.1 Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.1.2 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.1.3 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.2 South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 South Africa Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.2.2 South Africa Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.2.3 South Africa Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.3 United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.3.2 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.3.3 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.4 Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.1 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.4.2 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.4.3 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 CSL Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Seppic SA
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Croda International Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Novavax Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Phibro Animal Health Corp
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms